Get In Touch
Have any questions or comments about the content you see on this page?
Our News
March 16, 2022
At Alnylam, our Corporate Responsibility (CR) work is guided by the theme “Accepting Challenges to Improve the Health of Humanity” and articulates how we approach our work each day. It describes our commitment to tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good.
We began our CR journey in early 2020 through a combination of assessment and introspection leading to the development of an initial set of priorities for CR and establishing the organizational structures necessary to ensure that our actions matched our intentions, all of which we detailed in our first ever Corporate Responsibility Summary. In 2021, we built on this foundational work by hiring our first dedicated CR Director and formalizing a CR Steering Committee structure that aligned key Working Groups for each of our areas of focus in CR – patients, science, employees, communities, and planet.
Corporate responsibility has been a guiding principle for who we are and how we operate since Alnylam’s inception. In 2021, we integrated corporate responsibility even further into our company’s RNA by addressing health inequities in our communities, advancing efforts to reduce our environmental impact, and strengthening our commitment to diversity, equity, and inclusion. As we continue to drive these efforts forward for our patients, science, employees, communities, and planet, we are also committed to transparently and regularly communicating our progress.” - Yvonne Greenstreet, MBChB, MBA, CEO of Alnylam
Through the hard work of our teams who oversee, develop strategy for, and review reporting and key performance indicators surrounding their individual pillars, we are proud to share our first full Corporate Responsibility Report which you can download here.
Key highlights from this report include:
Our 2021 Corporate Responsibility Report provides more details on the specific actions we're taking and intend to take in 2022 and beyond. We are committed to transparently and regularly committing our progress and will continue to build our CR sophistication as we mature as a company and the world changes around us.
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site